Related references
Note: Only part of the references are listed.Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2018)
The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells
Joana Machado-Santos et al.
BRAIN (2018)
Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis
Hanane Touil et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
Joseph R. Berger et al.
JOURNAL OF NEUROVIROLOGY (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
Multiple Sclerosis: Mechanisms and Immunotherapy
Clare Baecher-Allan et al.
NEURON (2018)
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
J. Ciron et al.
REVUE NEUROLOGIQUE (2018)
Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Eva Havrdova et al.
NEUROLOGY (2017)
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J. Coles et al.
NEUROLOGY (2017)
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice A Nationwide Cohort Study From Sweden
Hjalmar Wadstroem et al.
JAMA INTERNAL MEDICINE (2017)
B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses
Sara J. Ireland et al.
JOURNAL OF NEUROIMMUNOLOGY (2016)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
Marie Colombe Agahozo et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Defining high, medium and low impact prognostic factors for developing multiple sclerosis
Mar Tintore et al.
BRAIN (2015)
Can we measure long-term treatment effects in multiple sclerosis?
Maria Pia Sormani et al.
NATURE REVIEWS NEUROLOGY (2015)
Immunopathology of multiple sclerosis
Calliope A. Dendrou et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Antibody-independent functions of B cells: a focus on cytokines
Ping Shen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true?
Mike P. Wattjes et al.
ANNALS OF NEUROLOGY (2014)
Progressive Multifocal Leukoencephalopathy after Natalizumab Discontinuation
Andrew J. Fine et al.
ANNALS OF NEUROLOGY (2014)
The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review
Yan Bao et al.
JOURNAL OF AUTOIMMUNITY (2014)
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Robert A. Fishman, MD (1924-2012) IN MEMORIAM
Stephen L. Hauser et al.
NEUROLOGY (2013)
Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity
Sara J. Ireland et al.
AUTOIMMUNITY (2012)
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis
Sung R. Choi et al.
BRAIN (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
David G. Maloney
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis A Retrospective Analysis of Patients Treated at a US Centre
Brandon A. Brown et al.
DRUG SAFETY (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Inflammatory Cortical Demyelination in Early Multiple Sclerosis
Claudia F. Lucchinetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2010)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Laura Piccio et al.
ARCHIVES OF NEUROLOGY (2010)
Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4+ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein
Christopher T. Harp et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Sara A. J. Thompson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Immunoglobulins and Complement in Postmortem Multiple Sclerosis Tissue
Michael H. Barnett et al.
ANNALS OF NEUROLOGY (2009)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
New approaches of B-cell-directed therapy: beyond rituximab
Thomas Dörner et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Homogeneity of active demyelinating lesions in established multiple sclerosis
Esther C. W. Breij et al.
ANNALS OF NEUROLOGY (2008)
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
B cells and multiple sclerosis
Diego Franciotta et al.
LANCET NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis
B Serafini et al.
BRAIN PATHOLOGY (2004)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Share Paper
